SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla informs about updates

18 Jul 2026 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informe3d that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the Company) located in Central Islip, Long Island, New York, USA, from 13th July, 2026 to 17th July, 2026 (EDT). The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the Company has received 1 inspectional observation in Form 483. The Company will work closely with the USFDA and is committed to address this comprehensively within stipulated time.

The above information is a part of company’s filings submitted to BSE. 

Cipla Share Price

1477.05 32.40 (2.24%)
29-Jul-2026 14:03 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1977.30
Dr. Reddys Labs. 1141.70
Cipla 1477.05
Lupin 2450.05
Zydus Lifesciences 1122.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: